Hangzhou Biotest Biotech Co.,Ltd. Stock

Equities

688767

CNE1000050H0

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. 06:00:00 2024-05-08 pm EDT 5-day change 1st Jan Change
30.87 CNY +3.76% Intraday chart for Hangzhou Biotest Biotech Co.,Ltd. +7.79% +1.98%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2022 1.9B 263M Sales 2023 442M 61.2M Capitalization 3.23B 447M
Net income 2022 774M 107M Net income 2023 107M 14.81M EV / Sales 2022 1.52 x
Net cash position 2022 2.03B 281M Net cash position 2023 1.9B 264M EV / Sales 2023 3 x
P/E ratio 2022
6.37 x
P/E ratio 2023
30.3 x
Employees 730
Yield 2022
4.76%
Yield 2023
-
Free-Float 33.12%
More Fundamentals * Assessed data
Dynamic Chart
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Hangzhou Biotest Biotech Co.,Ltd.'s Equity Buyback Plan announced on November 6, 2023. CI
Hangzhou Biotest Biotech Co.,Ltd.(XSSC:688767) dropped from S&P Global BMI Index CI
Biotest Biotech to Repurchase Up to 100 Million Yuan Shares MT
Hangzhou Biotest Biotech Co.,Ltd. announces an Equity Buyback for CNY 100 million worth of its shares. CI
Hangzhou Biotest Biotech Co.,Ltd. authorizes a Buyback Plan. CI
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hangzhou Biotest Biotech Co.,Ltd.(XSSC:688767) added to S&P Global BMI Index CI
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Hangzhou Biotest’s COVID-19 Antigen Home Test Kit Cleared by US FDA for Emergency Use MT
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Hangzhou Biotest Biotech Co.,Ltd.(SHSE:688767) added to Shanghai Stock Exchange Composite Index CI
More news
1 day+3.76%
1 week+7.79%
Current month+7.79%
1 month+19.79%
3 months+22.02%
6 months+1.38%
Current year+1.98%
More quotes
1 week
29.02
Extreme 29.02
31.09
1 month
22.85
Extreme 22.85
31.09
Current year
22.23
Extreme 22.23
31.36
1 year
22.23
Extreme 22.23
36.70
3 years
22.23
Extreme 22.23
152.50
5 years
22.23
Extreme 22.23
152.50
10 years
22.23
Extreme 22.23
152.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 10-01-31
Director of Finance/CFO 43 15-12-31
Chief Tech/Sci/R&D Officer 28 16-12-31
Members of the board TitleAgeSince
Chairman 62 15-09-27
Chief Executive Officer 47 10-01-31
Director/Board Member 34 15-08-31
More insiders
Date Price Change Volume
24-05-09 30.87 +3.76% 1,002,514
24-05-08 29.75 -0.70% 649,816
24-05-07 29.96 +1.77% 809,050
24-05-06 29.44 +2.79% 990,203

End-of-day quote Shanghai S.E., May 08, 2024

More quotes
Hangzhou Biotest Biotech Co Ltd is a company mainly engaged in the research and development (R&D), production and sales of point-of-care testing (POCT) diagnostic reagents. The Company's products include reproductive health testing series, such as human chorionic gonadotropin testing reagent and luteinizing hormone testing reagent, and drug abuse testing series, such as morphine testing reagent and cocaine testing reagent, and infectious disease testing series, such as adenovirus testing reagent and typhoid antibody testing reagent, and tumor marker testing series, such as alpha fetoprotein detection reagent, and myocardial marker detection series, such as dimer detection reagent and myocardial series detection reagent.
More about the company
  1. Stock Market
  2. Equities
  3. 688767 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW